We would like to welcome our new international- as well as Scandinavian owners after closing this funding round.
We are committed to the fight against advanced cancer and pain
- AbiprotTM breakthrough technology platform for functionality antibodies addressing the full human proteome
- Novel antibody therapeutics against undruggable targets, ion channels, and GPCRs
- OT-1096, an immunomodulatory small molecule that lowers regulatory T-cell numbers in tumor tissue